SanBio Co (JP:4592) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SanBio Co., Ltd. announced that the Fourth Pharmaceutical Affairs Council meeting of FY2024 included a report on the approved regenerative medicine product AKUUGOš¬š¬, a stem cell therapy for brain injury, which received conditional and time-limited approval. No significant discussion occurred regarding the reportās contents. SanBio, a leader in regenerative cell business, continues to focus on R&D for central nervous system disorders.
For further insights into JP:4592 stock, check out TipRanksā Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue